ライフサイエンスコーパス: diabetes complication

1 Skeletal muscle myopathy is a common diabetes complication.

2 IL-12 emerged as a critical player in type 2 diabetes complications.

3 ndothelial dysfunction-related microvascular diabetes complications.

4 GEs) in the skin and is a risk indicator for diabetes complications.

5 (amide), for the prevention and treatment of diabetes complications.

6 ators of pathological mechanisms involved in diabetes complications.

7 may be a potential predictor of the risk of diabetes complications.

8 be an initiating event in the development of diabetes complications.

9 y persistent hyperglycemia and contribute to diabetes complications.

10 rker of glycemic control and risk factor for diabetes complications.

11 upports GV as an independent risk factor for diabetes complications.

12 potential implications for the prevention of diabetes complications.

13 ATP generation in several target tissues of diabetes complications.

14 tential strategy to reduce the likelihood of diabetes complications.

15 athway and were enriched in genes related to diabetes complications.

16 Diabetes remission, relapse, and diabetes complications.

17 d to lncRNA-based therapies for inflammatory diabetes complications.

18 survival of beta-cells, and protects against diabetes complications.

19 re strongly implicated in the development of diabetes complications.

20 ationship between periodontitis severity and diabetes complications.

21 tasis and separately slow the development of diabetes complications.

22 e progression and have an increased risk for diabetes complications.

23 abolic changes underlying the development of diabetes complications.

24 essive symptoms are strongly associated with diabetes complications.

25 t increased risk of type 2 diabetes and many diabetes complications.

26 fense may play a role in the pathogenesis of diabetes complications.

27 e activation relevant to the pathogenesis of diabetes complications.

28 oposed as a mediator of neurodegeneration in diabetes complications.

29 R) has been implicated in the development of diabetes complications.

30 also measured the presence of self-reported diabetes complications.

31 ol pathway and preventing the development of diabetes complications.

32 t regimens is associated with a high risk of diabetes complications.

33 actices may not be optimal for prevention of diabetes complications.

34 hs; 22.4%), cancer (21 deaths; 19.6%), acute diabetes complications (19 deaths; 17.8%), and accidents

35 gnosis, the leading cause of death was acute diabetes complications (73.6%), while during the next 10

36 pecies may represent an important pathway in diabetes complications and a new mechanism in phagocyte-

37 d glycaemic control, which reduces long-term diabetes complications and could also improve tuberculos

38 effect than ARBs and ACE inhibitors on these diabetes complications and may be clinically more effica

39 diabetes and of poor diabetes outcomes (eg, diabetes complications and mortality).

40 of periodontal disease on glycaemic control, diabetes complications, and development of type 2 (and p

41 rglycemia-induced inflammation is central in diabetes complications, and monocytes are important in o

42 d chemokines relevant to the pathogenesis of diabetes complications are induced by HG via key signali

43 te the enhanced inflammation associated with diabetes complications are not completely understood.

44 s plays a pivotal role in the development of diabetes complications, both microvascular and cardiovas

45 ompound is worthy of further study to lessen diabetes complications but that dosage needs considerati

46 After 20 years' duration, chronic diabetes complications (cardiovascular, renal, or infect

47 glucose control markedly reduced the risk of diabetes complications compared with conventional therap

48 onset type 1 diabetes in the Epidemiology of Diabetes Complications (EDC) Study and was validated usi

49 expectancy of the Pittsburgh Epidemiology of Diabetes Complications (EDC) study cohort and quantify i

50 xamination of the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study cohort, 302 adults (m

51 nce data from the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study to investigate the wi

52 Subjects from the Epidemiology of Diabetes Complications (EDC) Study were clinically exami

53 Persons born to women with previous acute diabetes complications had a higher CHD risk than those

54 riving, initial cellular response underlying diabetes complications has been held for the past decade

55 rs7533564 was not associated with diabetes complications in DCCT/EDIC or with SF in subjec

56 ed glucose handling, insulin resistance, and diabetes complications in prediabetic DT/HF mice.

57 ls play a central role in the development of diabetes complications in the retina and nerve.

58 important role in the development of various diabetes complications, including atherosclerosis.

59 xygen species (ROS) are crucial in long-term diabetes complications, including peripheral artery dise

60 that plays a central role in the etiology of diabetes complications, inflammation, and neurodegenerat

61 The risk of long-term diabetes complications is not fully explained by diabete

62 iabetes, but the association with short-term diabetes complications is unclear.

63 Because the role of lncRNAs in diabetes complications is unknown, we further characteri

64 , with a concomitant 50% to 70% reduction in diabetes complications, may require close monitoring and

65 ations are reexamined, and a new concept for diabetes complications--mitochondrial hormesis--is prese

66 Although some type 1 diabetes complications (mortality, renal failure, and ne

67 and all hospital admissions related to acute diabetes complications (p = 0.008).

68 abolic memory (MM) is the phenomenon whereby diabetes complications persist and progress after glycem

69 The disease does not progress over time, and diabetes complications rarely develop.

70 moglobin glycation and have implications for diabetes complications risk and risk assessment.

71 value are a major determinant of the 89% of diabetes complications risk not captured by HbA1c.

72 , the risk increased among those with higher Diabetes Complications Severity Index scores (P = .0002)

73 he Pittsburgh, Pennsylvania, Epidemiology of Diabetes Complications Study of childhood-onset type 1 d

74 Participants from the Epidemiology of Diabetes Complications Study who were free of CAD at stu

75 GN AND Participants from the Epidemiology of Diabetes Complications Study with DNA available were stu

76 rticipants of the Pittsburgh Epidemiology of Diabetes Complications study with Hp genotyping availabl

77 l Pittsburgh Epidemiology of Childhood-Onset Diabetes Complications Study.

78 l roles in the initiation and progression of diabetes complications such as diabetes-associated ather

79 N3K may play a key role in the GGap and thus diabetes complications such that FN3K may be a potential

80 flected established pathogenic mechanisms of diabetes complications, such as elements of Janus kinase

81 hanisms may contribute to the development of diabetes complications, such as nephropathy.

82 e effective in preventing the progression of diabetes complications than currently available therapie

83 f people-who were generally at lower risk of diabetes complications-than the BTT.

84 For diabetes complications, the median follow-up time was 17

85 type 2 diabetes from the BErgamo NEphrologic Diabetes Complication Trial (BENEDICT), all of whom rece

86 2 diabetic patients from BErgamo NEphrologic DIabetes Complications Trial (BENEDICT).

87 ew of substantial mis-estimation of risks of diabetes complications using existing equations, we soug

88 Information on diabetes complications was obtained from national health

89 The association with acute pregestational diabetes complications was particularly strong, suggesti

90 disease duration of 15-25 years and minimal diabetes complications with an age-matched, nondiabetic

91 hypothesized that genetic predisposition to diabetes complications would be more evident among low-r

92 A second approach based on diabetes complications yielded a net value of $6931 per